Compounds > 5,6-methylenedioxy-2-aminoindane
Page last updated: 2024-12-07

5,6-methylenedioxy-2-aminoindane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5,6-methylenedioxy-2-aminoindane: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID125558
CHEMBL ID162375
CHEBI ID189818
SCHEMBL ID5318502
MeSH IDM0182949

Synonyms (29)

Synonym
AC-3402
mdai
6,7-dihydro-5h-cyclopenta[f][1,3]benzodioxol-6-amine
5,6-methylenedioxy-2-aminoindan
bdbm50010589
6,7-dihydro-5h-indeno[5,6-d][1,3]dioxol-6-ylamine
CHEMBL162375 ,
132741-81-2
CHEBI:189818
6,7-dihydro-5h-cyclopenta[][1,3]benzodioxol-6-amine
A806492
AKOS005762887
6,7-dihydro-5h-indeno(5,6-d)-1,3-dioxol-6-amine
5,6-methylenedioxy-2-aminoindane
5h-indeno(5,6-d)-1,3-dioxol-6-amine, 6,7-dihydro-
0dmj6g3xbf ,
unii-0dmj6g3xbf
6,7-dihydro-5h-cyclopenta(f)(1,3)benzodioxol-6-amine
SCHEMBL5318502
6,7-dihydro-5h-indeno[5,6-d][1,3]dioxol-6-amine
FQDRMHHCWZAXJM-UHFFFAOYSA-N
5h-indeno[5,6-d]-1,3-dioxol-6-amine, 6,7-dihydro-
DTXSID60157741
mdai; 5,6-methylenedioxy-2-aminoindane
5,6-methylenedioxy-2-aminoindane (mdai)
mdai (5,6-methylenedioxy-2-aminoindane) 1.0 mg/ml in acetonitrile
BCP06557
E10132
Q6715120

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Unexpectedly, 40mg/kg MDAI killed 90% of animals in the first behavioural test, hence LD50 tests were conducted which yielded 28."( Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): Pharmacokinetics, behaviour, thermoregulation and LD50 in rats.
Balíková, M; Čegan, M; Himl, M; Horsley, RR; Kuchař, M; Lhotková, E; Mikšátková, P; Páleníček, T; Tylš, F; Valeš, K; Žídková, M, 2016)		0.75
" The present study showed strong cytotoxic potential for the NPS 5F-PB-22 and MDAI, moderate effects for MDMA, MDPV, methylone, cathinone, 4-MEC, and mephedrone, and no toxic effects for methamphetamine."( Cytotoxicity of new psychoactive substances and other drugs of abuse studied in human HepG2 cells using an adopted high content screening assay.
Beck, A; Flockerzi, V; Maurer, HH; Meyer, MR; Richter, LHJ, 2019)		0.51

Dosage Studied

ExcerptRelevanceReference
" More importantly, if a subacute dosing regimen (every 12 hours for 4 days) was utilized, the combination of S-amphetamine with MDAI resulted in a marked long-term decrease in the levels of cortical, hippocampal and striatal 5-HT, 5-HIAA and the number of 5-HT uptake sites."( Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue.
Huang, XM; Johnson, MP; Nichols, DE, 1991)		0.28
" Metabolism of MDAI, which has been hitherto unexplored, was studied in rats dosed with a subcutaneous dose of 20 mg MDAI."( Study on the metabolism of 5,6-methylenedioxy-2-aminoindane (MDAI) in rats: identification of urinary metabolites.
Balíková, M; Dušek, M; Himl, M; Lhotková, E; Linhart, I; Páleníček, T; Váňa, L; Vetýška, M; Židková, M, 2017)		0.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzodioxoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID189911Tested for disruption in more than 50% rats trained to discriminate LSD from saline at a dose 9.36(uM/kg) (no. of animals =6)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID175188Percentage of animals disrupted was determined in groups of LSD trained rats at a dose of 4.68(uM/kg) (no. of animals = 15)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID190063Tested for stimulus generation in rats trained to discriminate +/-MDMA from saline at 2.34 (umol/kg), (number of animals = 10)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID175192Percentage of animals disrupted was determined in groups of MDMA trained rats at a dose 9.36 (uM/kg), (no.of animals=10)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID175189Percentage of animals disrupted was determined in groups of LSD trained rats at a dose of 9.36(uM/kg) (no. of animals =6)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID184520Monoamine levels in rat hippocampus were evaluated after subcutaneous administration of 40 mg/kg for 5-HIAA1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID175197Percentage of animals disrupted was determined in groups of MDMA trained rats at a dose 4.68 (uM/kg), (no.of animals=8)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID184521Monoamine levels in rat hippocampus were evaluated after subcutaneous administration of 40 mg/kg for 5-HT1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID190092Tested for stimulus generation in rats trained to discriminate LSD from saline at a dose 1.17 (umol/kg) (number of animals =16)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID190070Tested for stimulus generation in rats trained to discriminate +/-MDMA from saline at 4.68 (umol/kg), (number of animals = 8)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID184514Monoamine levels in rat brain were evaluated after subcutaneous administration of 40 mg/kg for 5-HIAA1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID184515Monoamine levels in rat brain were evaluated after subcutaneous administration of 40 mg/kg for 5-HT1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID184516Monoamine levels in rat brain were evaluated after subcutaneous administration of 40 mg/kg for DA1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID174867Hallucinogenic property was determined in groups of LSD trained rats and percentage of animals disrupted was reported at a dose 0.59(uM/kg), (number of animals = 11)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID184518Monoamine levels in rat brain were evaluated after subcutaneous administration of 40 mg/kg for HVA1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID189916Tested for stimulus generation in rats trained to discriminate +/-MDMA from saline at 1.17 (umol/kg), (number of animals = 8)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID184513Monoamine levels in at hippocampus were evaluated after subcutaneous administration of 40 mg/kg for NE1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID190096Tested for stimulus generation in rats trained to discriminate LSD from saline at a dose 2.34 (umol/kg) (number of animals = 10)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID175044Percentage of animals disrupted was determined in groups of LSD trained rats at a dose of 2.34(uM/kg) (no. of animals = 10)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID175042Percentage of animals disrupted was determined in groups of LSD trained rats at a dose of 1.17(uM/kg)(no. of animals =16)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID190090Tested for stimulus generation in rats trained to discriminate LSD from saline at a dose 0.59(uM/kg), (number of animals = 11)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID88605Bmax for compound was evaluated in rat hippocampal homogenate1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID205028Binding affinity was determined towards serotonin uptake site in presence of [3H]paroxetine radioligand in rat brain cortical homogenate1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID205029Binding affinity was determined towards serotonin uptake site in presence of [3H]paroxetine radioligand in rat hippocampal homogenate1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID184517Monoamine levels in rat brain were evaluated after subcutaneous administration of 40 mg/kg for DOPAC1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID175014Hallucinogenic property was determined in groups of MDMA trained rats and percentage of animals disrupted was reported at a dose 1.17 (umol/kg), (number of animals = 8)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID176238Inhibitory activity was determined MDMA trained rats1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID190247Tested for stimulus generation in rats trained to discriminate LSD from saline at a dose 4.68 (umol/kg),(number of animals = 15)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID190077Tested for stimulus generation in rats trained to discriminate +/-MDMA from saline at 9.36 (umol/kg), (number of animals = 10)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID184519Monoamine levels in rat brain were evaluated after subcutaneous administration of 40 mg/kg for NE1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID175191Percentage of animals disrupted was determined in groups of MDMA trained rats at a dose 2.34 (uM/kg), (no.of animals=10)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID51040Bmax for compound was evaluated in rat cortical homogenate1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (25.00)18.2507
2000's0 (0.00)29.6817
2010's12 (75.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.73 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (23.53%)6.00%
Case Studies3 (17.65%)4.05%
Observational0 (0.00%)0.25%
Other10 (58.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3,4-dihydroxyphenylacetic acid
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.. (3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.. dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.		1.9710catechols;
dihydroxyphenylacetic acid		human metabolite
3,4-methylenedioxyamphetamine
3,4-Methylenedioxyamphetamine: An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally.		2.3820benzodioxoles
n-methyl-3,4-methylenedioxyamphetamine
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.. 3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.		4.4970amphetamines;
benzodioxoles		neurotoxin
homovanillic acid
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.. homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.. homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.		1.9710guaiacols;
monocarboxylic acid		human metabolite;
mouse metabolite
hydroxyindoleacetic acid
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.		2.3920indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
acetaminophen
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.		2.2110acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
benzocaine
Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.. dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.. benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.		2.110benzoate ester;
substituted aniline		allergen;
antipruritic drug;
sensitiser;
topical anaesthetic
caffeine
[no description available]		2.0610purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
amphetamine
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.		1.9710primary amine
p-chloroamphetamine
p-Chloroamphetamine: Chlorinated analog of AMPHETAMINE. Potent neurotoxin that causes release and eventually depletion of serotonin in the CNS. It is used as a research tool.		1.9910
1-(3-trifluoromethylphenyl)piperazine
1-(3-trifluoromethylphenyl)piperazine: acts as serotonin agonist; structure. 1-(3-(trifluoromethyl)phenyl)piperazine : A N-arylpiperazine that is piperazine substituted by a 3-(trifluoromethyl)phenyl group at position 1. A serotonergic agonist used as a recreational drug.		2.0610(trifluoromethyl)benzenes;
N-arylpiperazine		environmental contaminant;
psychotropic drug;
serotonergic agonist;
xenobiotic
clorgyline
Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.. clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.		1.9910aromatic ether;
dichlorobenzene;
terminal acetylenic compound;
tertiary amino compound		antidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		2.2110naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
lysergic acid diethylamide
Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.. lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.		1.9710ergoline alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound		dopamine agonist;
hallucinogen;
serotonergic agonist
methamphetamine
Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.		4.6340amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
selegiline
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.		1.9910selegiline;
terminal acetylenic compound		geroprotector
paroxetine
Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.		1.9910aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
simvastatin
Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.		2.2110delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
cathinone
cathinone: alkaloid from khat shrub, Catha edulis; RN given refers to parent cpd without isomeric designation. cathinone : The S stereoisomer of 2-aminopropiophenone.		3.61202-aminopropiophenone;
monoamine alkaloid		central nervous system stimulant;
psychotropic drug
1-benzylpiperazine
1-benzylpiperazine: possesses psychomotor stimulant activity similar to dextroamphetamine; RN given refers to parent cpd; structure. 1-benzylpiperazine : A tertiary amino compound that is piperazine substituted by a benzyl group at position 1. It is a serotonergic agonist used as a recreational drug.		2.0610N-alkylpiperazineenvironmental contaminant;
psychotropic drug;
serotonergic agonist;
xenobiotic
2-aminoindan
[no description available]		2.110
n-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine
N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine: structure given in first source; RN given refers to (+-)-isomer		1.9710
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.5820
cocaine
Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.		2.1310benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
(3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
Fluvastatin: An indole-heptanoic acid derivative that inhibits HMG COA REDUCTASE and is used to treat HYPERCHOLESTEROLEMIA. In contrast to other statins, it does not appear to interact with other drugs that inhibit CYP3A4.. (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid diastereoisomer in which both chiral centres have S configuration.. fluvastatin : A racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin. An HMG-CoA reductase inhibitor, it is used (often as the corresponding sodium salt) to reduce triglycerides and LDL-cholesterol, and increase HDL-chloesterol, in the treatment of hyperlipidaemia.		2.2110(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
sodium oxybate
Sodium Oxybate: The sodium salt of 4-hydroxybutyric acid. It is used for both induction and maintenance of ANESTHESIA.		3.1610
mephedrone
mephedrone: a beta-keto (bk) designer drug; Central Nervous System Stimulants. mephedrone : An aromatic ketone that is propiophenone substituted at C-4 and at C-beta with methyl and methylamino groups respectively. It is a synthetic stimulant and entactogen drug of the amphetamine and cathinone classes.		4.430amphetamines;
aromatic ketone;
secondary amino compound		environmental contaminant;
xenobiotic
methylone
[no description available]		3.6120benzodioxoles
ConditionIndicatedRelationship StrengthStudiesTrials
Adipocere
[description not available]		02.1510
Chemical Dependence
[description not available]		04.5950
Substance-Related Disorders
Disorders related to substance use or abuse.		04.5950
Drug Overdose
Accidental or deliberate use of a medication or street drug in excess of normal dosage.		0310
Cyanosis
A bluish or purplish discoloration of the skin and mucous membranes due to an increase in the amount of deoxygenated hemoglobin in the blood or a structural defect in the hemoglobin molecule.		02.110
Methemoglobinemia
The presence of methemoglobin in the blood, resulting in cyanosis. A small amount of methemoglobin is present in the blood normally, but injury or toxic agents convert a larger proportion of hemoglobin into methemoglobin, which does not function reversibly as an oxygen carrier. Methemoglobinemia may be due to a defect in the enzyme NADH methemoglobin reductase (an autosomal recessive trait) or to an abnormality in hemoglobin M (an autosomal dominant trait). (Dorland, 27th ed)		02.110
Serotonin Syndrome
An adverse drug interaction characterized by altered mental status, autonomic dysfunction, and neuromuscular abnormalities. It is most frequently caused by use of both serotonin reuptake inhibitors and monoamine oxidase inhibitors, leading to excess serotonin availability in the CNS at the serotonin 1A receptor.		02.1310
Pyrexia
[description not available]		01.9910
Fever
An abnormal elevation of body temperature, usually as a result of a pathologic process.		01.9910